192 related articles for article (PubMed ID: 31082908)
21. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
22. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Mandarano M; Bellezza G; Belladonna ML; Vannucci J; Gili A; Ferri I; Lupi C; Ludovini V; Falabella G; Metro G; Mondanelli G; Chiari R; Cagini L; Stracci F; Roila F; Puma F; Volpi C; Sidoni A
Front Immunol; 2020; 11():839. PubMed ID: 32536910
[TBL] [Abstract][Full Text] [Related]
23. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
Mandarano M; Orecchini E; Bellezza G; Vannucci J; Ludovini V; Baglivo S; Tofanetti FR; Chiari R; Loreti E; Puma F; Sidoni A; Belladonna ML
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922388
[TBL] [Abstract][Full Text] [Related]
24. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
[TBL] [Abstract][Full Text] [Related]
25. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Mitra D; Horick NK; Brackett DG; Mouw KW; Hornick JL; Ferrone S; Hong TS; Mamon H; Clark JW; Parikh AR; Allen JN; Ryan DP; Ting DT; Deshpande V; Wo JY
Oncologist; 2019 Jun; 24(6):e275-e283. PubMed ID: 30755500
[TBL] [Abstract][Full Text] [Related]
26. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.
Toda Y; Kohashi K; Yamamoto H; Ishihara S; Ito Y; Susuki Y; Kawaguchi K; Kiyozawa D; Takamatsu D; Kinoshita I; Yamada Y; Maehara J; Kimura A; Tamiya S; Taguchi K; Matsunobu T; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
Sci Rep; 2021 Jul; 11(1):14821. PubMed ID: 34285260
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Rosenbaum MW; Gigliotti BJ; Pai SI; Parangi S; Wachtel H; Mino-Kenudson M; Gunda V; Faquin WC
Endocr Pathol; 2018 Mar; 29(1):59-67. PubMed ID: 29372535
[TBL] [Abstract][Full Text] [Related]
28. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E
J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146
[TBL] [Abstract][Full Text] [Related]
29. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
30. Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
Ma WJ; Wang X; Yan WT; Zhou ZG; Pan ZZ; Chen G; Zhang RX
World J Gastroenterol; 2018 May; 24(20):2181-2190. PubMed ID: 29853736
[TBL] [Abstract][Full Text] [Related]
31. IgG4-related disease is characterised by the overexpression of immunomodulatory proteins.
Arora K; Kulkarni A; Pankaj A; Desai N; Deshpande V
Histopathology; 2022 Oct; 81(4):486-495. PubMed ID: 34506637
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of PD-1 on Tumor-Infiltrating Lymphocytes in 433 Resected Esophageal Cancers.
Nomoto D; Baba Y; Okadome K; Yagi T; Kalikawe R; Kiyozumi Y; Harada K; Eto K; Hiyoshi Y; Nagai Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Watanabe M; Baba H
Ann Thorac Surg; 2022 Jan; 113(1):286-294. PubMed ID: 33482156
[TBL] [Abstract][Full Text] [Related]
33. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer.
Kim JW; Nam KH; Ahn SH; Park DJ; Kim HH; Kim SH; Chang H; Lee JO; Kim YJ; Lee HS; Kim JH; Bang SM; Lee JS; Lee KW
Gastric Cancer; 2016 Jan; 19(1):42-52. PubMed ID: 25424150
[TBL] [Abstract][Full Text] [Related]
34. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H
J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428
[TBL] [Abstract][Full Text] [Related]
35. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
Liu XQ; Lu K; Feng LL; Ding M; Gao JM; Ge XL; Wang X
Leuk Lymphoma; 2014 Feb; 55(2):405-14. PubMed ID: 23682557
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoints indoleamine 2,3-dioxygenase 1 and programmed death-ligand 1 in oral mucosal dysplasia.
Sieviläinen M; Passador-Santos F; Almahmoudi R; Christopher S; Siponen M; Toppila-Salmi S; Salo T; Al-Samadi A
J Oral Pathol Med; 2018 Sep; 47(8):773-780. PubMed ID: 29851145
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Hu C; Tian S; Lin L; Zhang J; Ding H
Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
[TBL] [Abstract][Full Text] [Related]
38. The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis.
Yu CP; Fu SF; Chen X; Ye J; Ye Y; Kong LD; Zhu Z
Cell Physiol Biochem; 2018; 49(1):134-143. PubMed ID: 30134237
[TBL] [Abstract][Full Text] [Related]
39. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
[TBL] [Abstract][Full Text] [Related]
40. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
